About Us | Contact

Mariam Enid Abreu Ruiz Investigator

Florida Hospital Zephyrhills NPI1740472695
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$137,622.21
from 105 payments in the last 6 years

Total Cash or Cash Equivalent

$136,436.71
from 94 payments in the last 6 years

Total In-kind Items & Services

$1,185.50
from 11 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
03/04/2021 Research Cash or cash equivalent $13666.17 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 834357215
01/13/2021 Research Cash or cash equivalent $9532.75 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 834357041
10/08/2020 Research Cash or cash equivalent Drug $28.40 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733484353
10/08/2020 Research Cash or cash equivalent Drug $12.04 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733484351
09/18/2020 Research Cash or cash equivalent Drug $206.85 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733484309
09/15/2020 Research Cash or cash equivalent Drug $82.75 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733484307
09/15/2020 Research Cash or cash equivalent Drug $14.16 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733484305
07/20/2020 Research Cash or cash equivalent Drug $24325.61 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733484215
07/28/2020 Research Cash or cash equivalent Drug $4.91 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733484213
07/17/2020 Research Cash or cash equivalent Drug $14.16 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733484211
06/09/2020 Research Cash or cash equivalent Drug $14.49 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733484121
06/09/2020 Research Cash or cash equivalent Drug $6.42 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733484119
04/24/2020 Research Cash or cash equivalent Drug $11.64 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483961
04/24/2020 Research Cash or cash equivalent Drug $24.36 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483959
04/24/2020 Research Cash or cash equivalent Drug $92.04 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483957
04/20/2020 Research Cash or cash equivalent Drug $32041.90 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483955
02/25/2020 Research Cash or cash equivalent Drug $19.32 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483667
02/25/2020 Research Cash or cash equivalent Drug $28.00 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483665
02/25/2020 Research Cash or cash equivalent Drug $16.28 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483663
02/25/2020 Research Cash or cash equivalent Drug $24.16 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483657
02/25/2020 Research Cash or cash equivalent Drug $40.52 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483655
02/25/2020 Research Cash or cash equivalent Drug $187.35 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483653
01/21/2020 Research Cash or cash equivalent Drug $38127.37 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483363
01/20/2020 Research Cash or cash equivalent Drug $20.10 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483361
01/20/2020 Research Cash or cash equivalent Drug $93.22 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483359
01/20/2020 Research Cash or cash equivalent Drug $127.10 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483357
01/08/2020 Research Cash or cash equivalent Drug $187.35 Details
Payment from Ichnos Sciences Inc.
Paymment Research Study GBR830-204
Payment Record ID 733483355
12/26/2019 Research Cash or cash equivalent $63.55 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435467
12/20/2019 Research Cash or cash equivalent $4.83 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435465
12/20/2019 Research Cash or cash equivalent $77.20 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435463
12/20/2019 Research Cash or cash equivalent $6.50 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435461
12/20/2019 Research Cash or cash equivalent $3.93 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435459
12/20/2019 Research Cash or cash equivalent $4.82 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435457
12/20/2019 Research Cash or cash equivalent $16.94 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435455
12/20/2019 Research Cash or cash equivalent $6.32 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435453
11/26/2019 Research Cash or cash equivalent $17.46 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435281
11/26/2019 Research Cash or cash equivalent $12.64 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435279
11/26/2019 Research Cash or cash equivalent $20.10 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435277
11/26/2019 Research Cash or cash equivalent $61.70 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435275
11/01/2019 Research Cash or cash equivalent $635.37 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435273
11/01/2019 Research Cash or cash equivalent $30.15 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435271
11/01/2019 Research Cash or cash equivalent $235.75 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435269
11/01/2019 Research Cash or cash equivalent $6.78 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435267
10/01/2019 Research Cash or cash equivalent $6000.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435119
10/31/2019 Research Cash or cash equivalent $6.85 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435117
10/31/2019 Research Cash or cash equivalent $7.86 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435115
10/31/2019 Research Cash or cash equivalent $8.73 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435113
10/31/2019 Research Cash or cash equivalent $12.64 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435111
10/31/2019 Research Cash or cash equivalent $187.35 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689435109
09/10/2019 Research Cash or cash equivalent $34.14 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434909
09/10/2019 Research Cash or cash equivalent $6868.19 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434907
09/30/2019 Research Cash or cash equivalent $142.58 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434905
09/30/2019 Research Cash or cash equivalent $14.49 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434903
09/30/2019 Research Cash or cash equivalent $2.71 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434901
09/30/2019 Research Cash or cash equivalent $187.35 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434899
08/27/2019 Research Cash or cash equivalent $423.58 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434667
08/27/2019 Research Cash or cash equivalent $20.56 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434665
08/27/2019 Research Cash or cash equivalent $13.35 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434663
08/27/2019 Research Cash or cash equivalent $12.62 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434657
08/27/2019 Research Cash or cash equivalent $21.10 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434655
08/27/2019 Research Cash or cash equivalent $6.78 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434653
08/19/2019 Research Cash or cash equivalent $50.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434651
07/25/2019 Research Cash or cash equivalent $2.71 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434365
07/25/2019 Research Cash or cash equivalent $187.35 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434363
07/02/2019 Research Cash or cash equivalent $94.22 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434361
06/28/2019 Research Cash or cash equivalent $423.58 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434085
06/28/2019 Research Cash or cash equivalent $100.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689434083
04/18/2019 Research Cash or cash equivalent $7.60 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433335
04/18/2019 Research Cash or cash equivalent $1.83 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433333
04/18/2019 Research Cash or cash equivalent $8.95 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433331
04/18/2019 Research Cash or cash equivalent $21.69 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433329
04/18/2019 Research Cash or cash equivalent $4.65 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433327
04/18/2019 Research Cash or cash equivalent $50.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433325
04/18/2019 Research Cash or cash equivalent $60.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433323
04/18/2019 Research Cash or cash equivalent $50.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433321
04/18/2019 Research Cash or cash equivalent $10.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433319
04/18/2019 Research Cash or cash equivalent $20.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433317
04/18/2019 Research Cash or cash equivalent $5.69 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433315
04/18/2019 Research Cash or cash equivalent $2.71 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433313
04/18/2019 Research Cash or cash equivalent $50.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433311
04/18/2019 Research Cash or cash equivalent $211.79 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433309
04/18/2019 Research Cash or cash equivalent $92.64 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433307
04/18/2019 Research Cash or cash equivalent $9.46 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433305
04/18/2019 Research Cash or cash equivalent $8.67 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433303
04/18/2019 Research Cash or cash equivalent $5.80 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433301
04/18/2019 Research Cash or cash equivalent $100.00 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433299
04/18/2019 Research Cash or cash equivalent $34.76 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433297
04/18/2019 Research Cash or cash equivalent $25.16 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433295
04/18/2019 Research Cash or cash equivalent $58.40 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433293
04/18/2019 Research Cash or cash equivalent $187.35 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433291
04/18/2019 Research Cash or cash equivalent $51.96 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433289
04/18/2019 Research Cash or cash equivalent $60.59 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433287
04/18/2019 Research Cash or cash equivalent $17.11 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433285
04/18/2019 Research Cash or cash equivalent $297.70 Details
Payment from Glenmark Pharmaceuticals Inc.
Paymment Research Study A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD)
Payment Record ID 689433283
07/19/2018 General (Non-Research) In-kind items and services Travel and Lodging $79.75 Details
Payment from AstraZeneca AB
Payment Record ID 562497173
07/17/2018 General (Non-Research) In-kind items and services Travel and Lodging $79.75 Details
Payment from AstraZeneca AB
Payment Record ID 562489077
07/18/2018 General (Non-Research) In-kind items and services Food and Beverage $40.00 Details
Payment from AstraZeneca AB
Payment Record ID 562111903
07/18/2018 General (Non-Research) In-kind items and services Travel and Lodging $237.63 Details
Payment from AstraZeneca AB
Payment Record ID 561616317
07/18/2018 General (Non-Research) In-kind items and services Food and Beverage $27.23 Details
Payment from AstraZeneca AB
Payment Record ID 561346495
07/17/2018 General (Non-Research) In-kind items and services Food and Beverage $135.00 Details
Payment from AstraZeneca AB
Payment Record ID 561164419
07/18/2018 General (Non-Research) In-kind items and services Travel and Lodging $249.60 Details
Payment from AstraZeneca AB
Payment Record ID 560425651
07/18/2018 General (Non-Research) In-kind items and services Food and Beverage $59.90 Details
Payment from AstraZeneca AB
Payment Record ID 560377661
07/18/2018 General (Non-Research) In-kind items and services Food and Beverage $27.23 Details
Payment from AstraZeneca AB
Payment Record ID 560175541
07/17/2018 General (Non-Research) In-kind items and services Travel and Lodging $237.63 Details
Payment from AstraZeneca AB
Payment Record ID 559716269
08/23/2016 General (Non-Research) In-kind items and services Food and Beverage $11.78 Details
Payment from Regeneron Healthcare Solutions, Inc.
Payment Record ID 366385938
;